Door-to-door tuberculosis (TB) screening and contact tracing can improve diagnosis rates, but must be paired with effective follow-up care to be successful, a new Cochrane Review has found.

Global rollout of rapid molecular tests for TB over the last 12 years: Cochrane Review summarizes research on recipient and provider views

Tuberculosis (TB) causes more deaths in people living with HIV than any other disease, with more than 300,000 deaths in 2017. When detected, early TB can be treated effectively; however, people with advanced HIV are at high risk of death, often without knowing they have TB. Diagnosis of TB in HIV-positive people is often complicated because they may not present with typical symptoms, and sputum-based test are not always effective because many have disease outside the lungs and may not be able to produce sputum.

Tuberculosis (TB) causes more deaths globally than any other infectious disease and is a top 10 cause of death worldwide. Globally in 2017, of the estimated 10 million people with TB, 3.6 million were not reported to national TB programmes, many of whom were not being diagnosed with their disease. When it is detected early and effectively treated, TB is largely curable, but in 2017, around 1.6 million people died of tuberculosis, including 300,000 people living with HIV.

LSTM's Dr Maxine Caws is co-lead investigator on an advanced genetics study published in Nature Genetics, which has shown that a virulent strain of tuberculosis (TB) has adapted to transmit among young adults in Ho Chi Minh City, Vietnam.

In a new Cochrane Review, researchers from Tanzania working with colleagues in LSTM have evaluated the effectiveness of strategies to improve people’s access to treatment for tuberculosis (TB).

Researchers from South Africa and Canada have carried out a Cochrane review update to assess the safety and effectiveness of corticosteroids for treating tuberculous pericarditis.

In a paper published in Scientific Reports scientists from LSTM’s Research Centre for Drugs and Diagnostics (RCDD) have described a new way of screening potential treatments for Tuberculosis (TB), which may assist in the identification and prioritisation of new therapies which could potentially reduce the duration of current TB treatment.